Lifeboat Foundation

Taking the supplement, dilation of subjects’ arteries improved by 42 percent, making their blood vessels, at least by that measure, look like those of someone 15 to 20 years younger. An improvement of that magnitude, if sustained, is associated with about a 13 percent reduction in heart disease, Rossman said. The study also showed that the improvement in dilation was due to a reduction in oxidative stress.

Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University of Colorado Boulder research.

The study, published this week in the American Heart Association journal Hypertension, adds to a growing body of evidence suggesting pharmaceutical-grade nutritional supplements, or nutraceuticals, could play an important role in preventing heart disease-the nation’s No. 1 killer. It also resurrects the notion that oral antioxidants, which have been broadly dismissed as ineffective in recent years, could reap measurable health benefits if properly targeted, the authors say.

Continue reading “Novel antioxidant makes old blood vessels seem young again” »

Elena Milova is at the Interventions to extend healthspan and lifespan 2018 conference in Kazan this week. This is an important conference in the aging research field, and it includes a variety of leading experts giving talks about their research. One of these experts is Andrei Gudkov, and Elena had the opportunity to talk with him about his research.

Dr. Andrei V. Gudkov, Ph.D., D.Sci, is a Scientific Co-Founder of Cleveland Biolabs, Inc. and has been its Chief Scientific Officer since June 2003. Dr. Gudkov serves as Chief Scientific Officer and Founder at Everon Biosciences, Inc. He co-founded Mega Biotech & Electronics Co., Ltd. and serves as its Chief Scientific Officer. Dr. Gudkov serves as Senior Vice President of Basic Science at Roswell Park Cancer Institute. He has over 25 years of experience in biomedical research. Prior to 1990, he worked with the National Cancer Research Center in Moscow (USSR), where he led a broad research program focused on virology and cancer drug resistance.

In 1990, he re-established his lab at the University of Illinois at Chicago, where he became a tenured faculty member in the Department of Molecular Genetics. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic Foundation, where he served as Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. He has served as a Director of Cleveland Biolabs, Inc. since June 2003.

Continue reading “Interventions to extend healthspan and lifespan 2018- Dr. Andrei Gudkov” »

The ability to perform simple daily tasks can make a big difference in people’s lives, especially for those with spinal cord injuries. A UCLA-led team of scientists reports that six people with severe spinal cord injuries—three of them completely paralyzed—have regained use of their hands and fingers for the first time in years after undergoing a nonsurgical, noninvasive spinal stimulation procedure the researchers developed.

At the beginning of the study, three of the participants could not move their fingers at all, and none could turn a doorknob with one hand or twist a cap off a plastic water bottle. Each of them also had great difficulty using a cellphone. After only eight researcher-led training sessions with the spinal stimulation, all six individuals showed substantial improvements. The study participants had chronic and severe paralysis for more than one year, and some for more than 10 years.

From before the first session to the end of the last session, the participants improved their grip strength.

Continue reading “Noninvasive spinal stimulation method enables paralyzed people to regain use of hands, study finds” »

Hard to believe but some people are worried that when rejuvenation biotechnology is available they may be forced to use it.

Might rejuvenation become an imposition?

Suppose that, on a nice day not too far into the future, while everything is going reasonably well in your life and you are enjoying yourself, you walk into the doctor’s office for a regular checkup. The doctor finds nothing wrong with you, but in order to minimize your risk of developing diseases that are likely to strike people in your age range, she recommends that you undergo senolytic treatment. The treatment is safe, with no serious adverse effects, it is administered simply through injections, and it is either state-subsidized or otherwise affordable. In your opinion, what are the odds that you would refuse the doctor’s prescription and say that you’d rather take the risk of getting sick?

Continue reading “Some People Worry if Rejuvenation is Available they May be Forced to Use it” »

Detailed images of the anti-ageing enzyme telomerase are a drug designer’s dream.

A team of researchers, including professor Steve Horvath, the pioneer of the epigenetic clock, report in this new paper about an improved version of that clock [1]. His original epigenetic clock measures the age of a person by looking at DNA methylation patterns; these patterns correlate closely with the actual age of a person, with a margin of error of around two years or so.

Since the original clock was first created, work has continued on refining the process and how aging is measured. In terms of aging biomarkers, it is generally considered the gold standard, given how reliable it is as a way to determine biological age.

While chronological age is linked to the likelihood of us developing age-related diseases and dying, it is important to distinguish the difference between chronological age and biological age. Individuals of the same chronological age may not age in quite the same way or even at the same rate, showing differences in their susceptibility to different age-related diseases.

An interview from the recent Ending Aging conference in Berlin with Keith Comito which we did in collaboration with Anna Dobryukha from Komsomolskaya Pravda.

The Undoing Aging conference, a collaboration between the SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, took place on March 15–17 in Berlin, which saw many researchers, advocates, investors, and other important members of the longevity community gather together to learn about the latest progress in rejuvenation biotechnology.

As we had arranged a travel grant for Anna Dobryukha, one of the best Russian journalists writing about aging, longevity, and rejuvenation research, to join us, it made sense to collaborate with her on the most interesting interviews. Anna works for Komsomolskaya Pravda, one of the largest Russian publishing houses, which has a newspaper, a radio station, and a website with over 40 million readers. Anna has also published an article based on this and other interviews taken during the conference which you can find here.

Continue reading “Undoing Aging with Keith Comito” »

Scientists at New York’s Albert Einstein College of Medicine have conducted experiments and found that stem cell implants in the brains of mice can stop aging and help the treated animals remain fitter for longer.

What part of the brain controls aging?

The experiments have helped researchers identify that a part of the brain called the hypothalamus is intimately involved in the aging process. The investigators hope to launch trials in humans to see whether similar treatments with neural stem cells can prolong the life of treated individuals.

Continue reading “Stem Cell Implants in the Brain Could Delay Aging” »

Wilmington, DE, April 19, 2018 — Scientists at Christiana Care Health System’s Gene Editing Institute have developed a potentially breakthrough CRISPR gene-editing tool. It could allow researchers to take fragments of DNA extracted from human cells, put them into a test tube, and quickly and precisely engineer multiple changes to the genetic code, according to a new study published today in the CRISPR Journal.

Investigators at the Gene Editing Institute, which is part of the Helen F. Graham Cancer Center & Research Institute at Christiana Care, said their new “cell-free” CRISPR technology is the first CRISPR tool capable of making multiple edits to DNA samples “in vitro,” which means in a test tube or petri dish. The advance could have immediate value as a diagnostic tool, replicating the exact genetic mutations found in the tumors of individual cancer patients. Mutations that cause cancer to spread can differ from patient to patient, and being able to quickly identify the correct mutation affecting an individual patient can allow clinicians to implement a more targeted treatment strategy.

“With this new advance, we should be able to work with laboratory cultures and accomplish gene edits in less than a day, significantly reducing the time required for diagnostics compared to other CRISPR tools, and with much greater precision,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and principal author of the study. “This is particularly important for diagnostics linked to cancer care where time is critical.”